Loading stock data…
Iovance Biotherapeutics (IOVA)
$4.99-0.14 (-2.73%)
Market ClosedLast close Jul 24
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Iovance Biotherapeutics, Inc. in the Healthcare sector is trading at $4.99 with a market capitalization of $1.8B. Wall Street consensus targets $8.80 (10 analysts), implying a +76.4% move over the next 12 months. The stock is currently near its 52-week high of $5.64, remaining 54.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +76.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $71.43M↓ | $86.77M↑ | $67.45M↑ | $59.95M↑ | $49.32M |
| Gross Profit | $28.93M↓ | $43.66M↑ | $28.98M↑ | $3.29M↓ | $6.61M |
| Operating Income | -$81.04M↓ | -$73.46M↑ | -$89.76M↑ | -$113.77M↑ | -$121.22M |
| Net Income | -$79.05M↓ | -$71.90M↑ | -$91.25M↑ | -$111.66M↑ | -$116.16M |
Peer Comparison
JNJUNHPFE
Fundamentals
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the Unite...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.77B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.03%
Volume
Today's trading volume
9.32M
Recent News
Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here’s What’s Important to Note
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Best Penny Stocks to Invest In According to Billionaires. Recently, on June 30, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) updated its corporate presentation, highlighting its position as a global leader in tumor-infiltrating lymphocyte cell therapy. The update noted that the company has now treated more than 1,500 patients through […]
This Stock Is Up 74% This Year: Is It Too Late to Buy?
The biotech is clearly innovative, but sometimes that's not enough.
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026.
Iovance (IOVA) Surges 9.4% on Regulatory Nod
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 10 Resilient Stocks Beating Market Slump. Iovance Biotherapeutics saw its share prices increase by 9.36 percent to close at $4.44 apiece, as investors positioned portfolios ahead of the end of the second quarter, supported by a recent regulatory approval that opened the door for its expansion into […]
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.